Stock listing

NASDAQ:BEAM Beam Therapeutics Inc. Stock

Home listing (NASDAQ) of Beam Therapeutics Inc.

Follow Beam Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BEAM

$20.90 USD -0.11 (-0.5%)

Close on Nov 20, 2026

Past year +1.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$20.54 – $22.10 USDNov 20, 2026
Volume
3.88M sharesNov 20, 2026
Market cap
$2.16B USDAt the close on Nov 20, 2026 · price × 103.5M shares outstanding
52-week range
$20.39 – $38.26 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$51.21M USDMedian day 1.67M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Beam Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BEAM · Home$20.90 USD-0.11 (-0.5%)3,882,474$20.54$22.10$20.54$21.01Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BEAM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$20.90-0.11-0.5%$20.54$22.10$20.543,882,474
$21.01+0.36+1.7%$20.76$22.40$20.664,863,844
$20.65-0.29-1.4%$20.83$22.05$20.544,125,398
$20.94-1.89-8.3%$22.43$22.70$20.653,316,371
$22.83-1.20-5.0%$24.03$24.06$22.812,044,828
$24.03-1.78-6.9%$25.06$25.15$23.861,506,295
$25.81+0.66+2.6%$25.47$26.07$24.681,582,833
$25.15-1.87-6.9%$26.45$27.00$23.603,115,526
$27.02+0.61+2.3%$26.79$27.39$25.961,288,080
$26.41+0.54+2.1%$26.07$26.75$25.861,982,824
$25.87-1.92-6.9%$27.37$27.48$24.882,988,339
$27.79+1.46+5.5%$27.06$28.00$26.261,347,633
$26.33+0.46+1.8%$26.26$27.20$25.991,427,309
$25.87-1.36-5.0%$27.45$27.67$25.791,439,270
$27.23-1.61-5.6%$28.27$28.80$26.431,497,886
$28.84+0.06+0.2%$28.72$29.76$28.401,995,700
$28.78+3.88+15.6%$24.61$28.86$24.505,003,200
$24.90+1.11+4.7%$23.73$25.09$23.392,750,600
$23.79-0.26-1.1%$24.00$24.11$23.651,400,500
$24.05-0.51-2.1%$24.00$24.14$23.241,596,100
$24.56-0.28-1.1%$24.39$25.29$24.001,383,600
$24.84-0.09-0.4%$24.83$25.20$24.501,167,700
$24.93+0.74+3.1%$24.00$25.06$23.611,479,500
$24.19+0.72+3.1%$23.89$24.38$23.501,316,500
$23.47-1.26-5.1%$24.56$24.56$23.161,645,800
$24.73+1.08+4.6%$23.51$24.98$23.201,779,900
$23.65-0.78-3.2%$24.13$24.26$23.281,660,700
$24.43-0.70-2.8%$24.88$24.93$24.081,667,900
$25.13-0.57-2.2%$25.63$26.09$24.941,412,800
$25.70+1.10+4.5%$24.72$26.23$24.551,800,200
$24.60-0.17-0.7%$24.26$24.69$23.912,425,900
$24.77-0.46-1.8%$24.64$25.37$24.452,342,400
$25.23-0.44-1.7%$26.80$26.94$24.872,516,700
$25.67+1.17+4.8%$24.48$26.04$23.831,999,200
$24.50+0.11+0.5%$25.00$25.48$24.211,497,500
$24.39-0.06-0.2%$24.24$24.98$23.961,693,300
$24.45-0.07-0.3%$24.79$25.20$24.411,555,600
$24.52+0.29+1.2%$23.88$24.76$23.881,637,100
$24.23-0.04-0.2%$24.02$24.66$23.441,273,600
$24.27-0.39-1.6%$24.97$24.97$23.751,217,900
$24.66+0.29+1.2%$23.88$24.81$23.162,283,000
$24.37-1.56-6.0%$25.75$26.24$24.221,896,000
$25.93+0.67+2.7%$25.62$26.50$25.071,987,800
$25.26+0.31+1.2%$25.45$25.66$24.831,701,300
$24.95+0.28+1.1%$24.92$25.18$24.262,286,600
$24.67+1.57+6.8%$24.28$25.50$24.052,424,400
$23.10-0.12-0.5%$23.41$23.65$22.671,817,700
$23.22-0.90-3.7%$23.82$23.84$22.862,584,100
$24.12+0.13+0.5%$24.02$24.93$23.991,457,100
$23.99-0.38-1.6%$24.64$24.76$23.951,193,700
$24.37-0.805-3.2%$24.76$24.89$23.981,980,300
$25.18-1.655-6.2%$26.70$26.70$25.112,842,800
$26.83-2.83-9.5%$26.76$27.30$25.046,174,900
$29.66+0.20+0.7%$28.91$29.97$28.911,181,600
$29.46+0.17+0.6%$29.49$29.65$28.021,266,600
$29.29+0.27+0.9%$29.27$30.18$28.231,292,200
$29.02-0.41-1.4%$28.82$29.56$28.70887,900
$29.43+0.11+0.4%$28.82$29.82$28.331,308,000
$29.32-1.16-3.8%$29.53$30.50$29.011,330,100
$30.48+0.29+1.0%$30.14$30.82$29.721,268,800
$30.19-0.84-2.7%$30.96$31.02$29.761,386,700
$31.03+2.70+9.5%$28.94$31.48$28.782,188,665
$28.33-1.43-4.8%$29.25$29.35$28.231,245,306
$29.76+1.37+4.8%$28.74$30.50$28.612,457,300
$28.39-0.68-2.3%$28.08$29.10$26.982,409,500
Ticker
NASDAQ:BEAM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Beam Therapeutics Inc. news

Beam Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 160 in all · newest Nov 10, 2026 · oldest 2020
Calls
2 calls with a replay · 2 with a transcript · latest Feb 24, 2026
Decks
16 decks · latest September 2026

Where Beam Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BEAM · Home listing · This pageNASDAQUnited StatesUSD
BMV:BEAMBMVMexicoMXN
BOATS:BEAMBOATSUnited StatesUSD
BIVA:BEAMBIVAMexicoMXN

Valuation

EV/sales 8.3× against a median of 18.8×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.22B USD
P/E
Loss
EV/sales
8.3×
EV/EBITDA
Negative EBITDA
Price/book
2.3×
Gross margin
100.0%
Operating margin
−267.7%
Net margin
−73.9%
Debt to equity
0.1×
Beta vs S&P 500
1.90

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Beam Therapeutics Inc. · NASDAQ:BEAMUS$2.16BUS$1.22Bn/a8.3×n/a2.3×−73.9%0.1×1.90
InSilico Medicine Cayman TopCo · HKEX:3696US$2.29BUS$1.70Bn/a30.3×n/a4.2×−626.5%0.0×n/a
Arcus Biosciences, Inc. · NYSE:RCUSUS$2.25BUS$1.72Bn/a17.2×n/a6.3×−453.0%0.3×1.37
SK bioscience Co.,Ltd. · KRX:302440US$2.24BUS$2.02Bn/a4.1×n/a1.7×−12.8%0.3×n/a
NewAmsterdam Pharma Company N.V. · NASDAQ:NAMSUS$2.20BUS$1.57Bn/a60.6×n/a3.5×−789.9%0.0×1.41
Lakefront Biotherapeutics · EURONEXT:LKFTUS$2.20B−US$260.7M3.4×−0.2×n/a0.6×60.2%0.0×n/a
Pharvaris N.V. · NASDAQ:PHVSUS$2.20BUS$1.89Bn/an/an/a7.5×n/a0.0×0.76
BioArctic AB Class B · OMXSTO:BIOA_BUS$2.19BUS$2.00B212×20.4×90.0×11.1×10.5%0.0×n/a
Celldex Therapeutics, Inc. · NASDAQ:CLDXUS$2.15BUS$1.50Bn/an/an/a3.3×n/a0.0×1.07
Palvella Therapeutics, Inc. · NASDAQ:PVLAUS$2.09BUS$1.85Bn/an/an/a10.6×n/a0.0×1.50
Regencell Bioscience Holdings Limited · NASDAQ:RGCUS$2.07BUS$2.06Bn/an/an/a155×n/a0.0×1.57
Median of the othersUS$2.20BUS$1.79B108×18.8×90.0×5.2×−232.9%0.0×1.39

Forecasts

12 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
49.85 USD · Analysts' mean
EPS, year to Dec 2026
-4.55 · 15 analysts
Revenue, year to Dec 2026
38.48M · 13 analysts

Team and board

Officers

OfficerRole
John EvansChief Executive Officer and Board Member
Sravan EmanyChief Financial Officer
Giuseppe CiaramellaPresident
Christine BellonChief Legal Officer
Bethany CavanaghSenior Vice President of Finance, Treasurer and Principal Accounting Officer
Amy SimonChief Medical Officer
Eric FosterChief Commercial Officer
Gopi ShankerChief Scientific Officer
Manmohan SinghChief Technology Officer
Susan O’ConnorChief Human Resources Officer

Board

DirectorRole
Chirfi GuindoBoard Member
Christi ShawBoard Member
Graham CooperBoard Member
John EvansChief Executive Officer and Board Member
John MaraganoreBoard Member
Kate WalshBoard Member
Mark FishmanIndependent Lead Director

Events

Calls

CallWhenStatus
Beam Therapeutics (NASDAQ:BEAM) Q4 2025 Earnings CallTue, Feb 24, 2026 · 8:00 AM ETReplay
Beam Therapeutics (NASDAQ:BEAM) Q3 2024 Earnings CallTue, Nov 05, 2024 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 3, 2026 · Before open+1.8%
Q2 2026Aug 4, 2026 · Before open+9.4%
Q1 2026May 7, 2026 · Before open−2.7%
Q4 2025Feb 24, 2026+4.5%
Q3 2025Nov 4, 2025 · Before open−6.2%
Q2 2025Aug 5, 2025 · Before open−2.2%
Q1 2025May 6, 2025 · Before open−19.3%
Q4 2024Feb 25, 2025 · Before open−3.1%
Q3 2024Nov 5, 2024 · Before open−1.8%
Q2 2024Aug 6, 2024 · Before open−0.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · Before open−1.1%
Q4 2023Feb 27, 2024 · Before open+25.9%
Q3 2023Nov 8, 2023 · Before open−8.4%
Q2 2023Aug 8, 2023 · Before open+2.8%
Q1 2023May 10, 2023 · Before open+3.9%
Q4 2022Feb 28, 2023 · Before open+3.2%
Q3 2022Nov 7, 2022 · Before open−11.4%
Q2 2022Aug 9, 2022 · Before open−4.3%
Q1 2022May 9, 2022 · Before open−6.7%
Q4 2021Feb 28, 2022 · Before open+4.8%

Open Events

Decks

DeckKindSlidesDate
European Respiratory Society (ERS) Congress 2026Conference9 slidesSeptember 2026
ATS 2026Conference21 slidesMay 2026
FY 2025 Earnings PresentationEarnings39 slidesFeb 24, 2026
Investor Presentation (January 2026)Investor deck27 slidesJan 12, 2026
67th ASH Annual Meeting 2025Conference15 slidesDecember 2025
2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient CongressConference20 slidesMay 2025
Corporate Update (January 2025)Corporate update39 slidesJan 13, 2025
66th ASH Annual Meeting 2024Conference17 slidesDecember 2024
Q3 2024 Earnings PresentationEarnings38 slidesNov 5, 2024
Alpha-1 National Conference 2024Conference21 slidesJun 8, 2024
All 16 decks
DeckKindSlidesDate
J.P. Morgan Healthcare Conference January 2024Conference26 slidesJan 8, 2024
Investor Presentation (October 2023)Investor deck26 slidesOct 19, 2023
Investor Presentation (January 2023)Investor deck25 slidesJan 9, 2023
Corporate Update (January 2022)Corporate update26 slidesJan 10, 2022
Investor Presentation (January 2021)Investor deck34 slidesJan 12, 2021
Technical Presentation (December 2020)Technical12 slidesDecember 2020

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: about US$500M · US$28.48 a share · J.P. Morgan +4
Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Cantor (co-lead), Citigroup (co-lead), Wells Fargo Securities (co-lead)
Use of proceeds: Advancing its base editing platform and programs, BEAM-101 BLA and pre-commercial work, BEAM-302 and ESCAPE trials, and general corporate purposes
Mar 10, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Feb 5, 2020.

Price
US$17.00 a share
Shares offered
10,588,236 shares of common stock
Offering size
US$180 million
Underwriters' option
Up to 1,588,235 more shares
Listing
BEAM on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Jefferies, Barclays, Wedbush PacGrow · In the order on the cover
Shares delivered
On or about Feb 10, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceJul 29, 2019
Filed publiclySep 27, 2019
Amended 4 timesNewest Feb 5, 2020
Shares registered with an exchangeJan 31, 2020
Declared effective by the SECFeb 5, 2020
Final prospectus, with the priceFeb 7, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Feb 7, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue139.7M63.5M377.7M60.9M51.8M24.0K18.0K0
Cost of revenue22.3M367.6M437.4M311.6M232.1M103.2M54.6M33.9M11.0K
Gross profit117.4M-304.0M377.7M-250.7M-180.3M-103.2M-54.6M-33.9M-11.0K
Research and development409.6M367.6M437.4M311.6M387.1M103.2M54.6M33.9M5.86M
Selling, general and administrative113.8M111.5M116.8M87.8M57.2M29.6M20.6M11.9M2.02M
Operating income-383.7M-415.6M-176.5M-338.5M-392.5M-132.8M-75.2M-45.7M-8.60M
Depreciation and amortization22.3M21.9M20.0M14.1M7.45M4.74M3.50M650.0K11.0K
EBITDA-361.4M-393.6M-156.5M-324.3M-385.0M-128.0M-71.7M-45.1M-8.59M
Interest expense43.7M49.1M46.7M15.3M9.00K1.57M187.0K00
Income before tax-80.0M-376.7M-131.2M-260.2M-370.6M-194.6M-78.3M-116.7M-8.73M
Income tax039.0K1.37M3.41M000-71.0M500.0K
Net income-80.0M-376.7M-132.5M-289.1M-370.6M-194.6M-78.3M-115.3M-8.73M
Earnings per share, basic-0.81-4.58-1.72-4.13-5.77-4.19-14.05-3.28-0.67
Earnings per share, diluted-0.81-4.58-1.72-4.13-5.77-4.19-14.05

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents294.9M282.0M435.9M232.8M560.0M162.2M37.2M146.4M1.90M
Short-term investments950.3M568.8M754.0M845.4M405.7M137.5M54.6M
Receivables0300.0M0
Inventory-607.4M
Current assets1.27B878.1M1.21B1.09B1.27B308.3M94.5M148.3M2.04M
Property, plant and equipment104.5M111.4M125.0M115.6M84.3M38.5M24.3M16.9M
Total assets1.48B1.10B1.46B1.34B1.47B451.7M156.1M167.0M2.40M
Accounts payable10.2M3.87M1.62M9.03M7.47M6.31M7.85M7.35M726.0K
Current liabilities96.9M182.1M205.6M223.6M213.4M102.3M29.1M25.6M6.57M
Long-term debt3.01M5.29M4.41M
Total debt293.9M161.4M172.7M179.0M147.6M107.6M31.2M1.01M
Total liabilities242.8M370.3M478.4M608.2M647.7M206.1M55.2M33.0M6.58M
Shareholders' equity1.24B733.5M981.3M733.5M826.7M245.6M-201.1M134.0M-4.18M
Shares outstanding101.7M83.6M81.6M71.3M68.4M57.3M7.33M35.1M13.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-345.1M-347.2M-149.2M22.5M-66.3M-95.7M-72.0M-20.3M-2.71M
Capital spending-14.9M-8.95M-33.7M-49.0M-46.8M-16.4M-12.5M-13.1M-346.0K
Free cash flow-360.0M-356.2M-182.9M-26.4M-113.1M-112.1M-84.5M-33.4M-3.05M
Cash from investing-121.4M185.0M71.8M-461.3M-294.1M-100.1M-66.7M-13.4M-346.0K
Cash from financing478.0M7.74M276.4M111.6M756.1M322.3M41.3M179.7M4.98M
Dividends paid-12.7M
Share buybacks758.3M-25.2M
Change in cash11.5M-154.5M199.1M-327.2M395.7M126.5M-97.4M146.0M1.93M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
8-K · Current reportNov 3, 2026ResultsSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
144 · Notice of proposed saleOct 16, 2026Other filingsSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026ResultsSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
144 · Notice of proposed saleJul 27, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 8, 2026Meeting outcomeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 17, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 17, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2026Meeting noticeSEC
144 · Notice of proposed saleApr 14, 2026Other filingsSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
144 · Notice of proposed saleMar 30, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
8-K · Current reportMar 5, 2026Current reportSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
S-8 · Registration statement for employee plansFeb 24, 2026Offer documentSEC
10-K · Annual reportFeb 24, 2026Annual reportSEC
8-K · Current reportFeb 24, 2026ResultsSEC
8-K · Current reportFeb 12, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
8-K · Current reportFeb 5, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 3, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
144 · Notice of proposed saleJan 30, 2026Other filingsSEC
144 · Notice of proposed saleJan 29, 2026Other filingsSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
8-K · Current reportDec 11, 2025Acquisition or disposalSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025ResultsSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
144 · Notice of proposed saleOct 2, 2025Other filingsSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
4 · Change in ownershipAug 1, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
8-K · Current reportJul 3, 2025FinancingSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
ARS · Annual report to shareholdersApr 18, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 18, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 18, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
3 · Initial statement of ownershipApr 10, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
144 · Notice of proposed saleApr 2, 2025Other filingsSEC
4/A · Change in ownership, amendedApr 2, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 2, 2025Big-stake noticeSEC
144 · Notice of proposed saleMar 31, 2025Other filingsSEC
144 · Notice of proposed saleMar 31, 2025Other filingsSEC
144 · Notice of proposed saleMar 31, 2025Other filingsSEC
144 · Notice of proposed saleMar 31, 2025Other filingsSEC
424B5 · ProspectusMar 10, 2025Offer documentSEC
8-K · Current reportMar 10, 2025Material contractSEC
FWP · Free writing prospectusMar 10, 2025Offer documentSEC
424B5 · ProspectusMar 10, 2025Offer documentSEC
8-K · Current reportMar 10, 2025Current reportSEC
S-8 · Registration statement for employee plansFeb 25, 2025Offer documentSEC
10-K · Annual reportFeb 25, 2025Annual reportSEC
8-K · Current reportFeb 25, 2025ResultsSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleFeb 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
144 · Notice of proposed saleJan 30, 2025Other filingsSEC
8-K · Current reportJan 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 10, 2025Big-stake noticeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
144 · Notice of proposed saleDec 30, 2024Other filingsSEC
144 · Notice of proposed saleDec 30, 2024Other filingsSEC
4 · Change in ownershipDec 19, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 19, 2024Insider tradeSEC
8-K · Current reportDec 9, 2024Current reportSEC
8-K · Current reportDec 6, 2024Management or board changeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 4, 2024Insider tradeSEC
8-K · Current reportDec 4, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
4 · Change in ownershipNov 8, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 7, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2024Quarterly reportSEC
8-K · Current reportNov 5, 2024Current reportSEC
8-K · Current reportNov 5, 2024Current reportSEC
8-K · Current reportNov 5, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedOct 21, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 17, 2024Big-stake noticeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
144 · Notice of proposed saleOct 15, 2024Other filingsSEC
144 · Notice of proposed saleOct 7, 2024Other filingsSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
144 · Notice of proposed saleSep 30, 2024Other filingsSEC
4 · Change in ownershipSep 3, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 19, 2024Insider tradeSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
8-K · Current reportJul 15, 2024Management or board changeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
144 · Notice of proposed saleJun 27, 2024Other filingsSEC
8-K · Current reportJun 10, 2024Meeting outcomeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC

This page holds 200 of 515 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Beam Therapeutics Inc.’s releases · as of Mar 10, 2025

Common shares
103,495,644
Fully diluted
103,495,644

Fully diluted

LineShares
Common shares103,495,644

Share count over time

CountShares
Nov 22, 2026103,495,644

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
Fidelity12.9MUS$316M+317KNov 10, 2026
ARK11.8MUS$289M+1.57MNov 13, 2026
Vanguard10.4MUS$254M−14,219Nov 13, 2026
Farallon Capital Management, L.L.C.10.3MUS$251M+40,000Nov 16, 2026
BlackRock9.12MUS$223M+122KNov 13, 2026
State Street5.92MUS$145M+93,370Nov 12, 2026
ARCH Venture Management, LLC4.54MUS$111MNo changeNov 16, 2026
Kynam Capital Management, LP3.93MUS$96.2M+1.09MNov 16, 2026
Sumitomo Mitsui Trust Group, Inc.3.35MUS$81.9M−106KOct 29, 2026
Amova Asset Management Americas, Inc.3.35MUS$81.8M−106KNov 13, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Geode Capital2.51MUS$61.5M−82,904Nov 6, 2026
T. Rowe Price2.18MUS$53.4M−1.23MNov 16, 2026
Dimensional2.17MUS$53M−59,622Nov 4, 2026
Morgan Stanley1.97MUS$48.2M+19,272Nov 13, 2026
UBS1.84MUS$45.1M−284KNov 16, 2026
Two Sigma1.64MUS$40.1M+253KNov 16, 2026
Casdin Capital, LLC1.5MUS$36.7M+150KNov 16, 2026
Goldman Sachs1.34MUS$32.8M+31,240Nov 16, 2026
Redmile Group, LLC1.06MUS$26M−102KNov 16, 2026
Deep Track Capital, LP1MUS$24.4MNo changeNov 16, 2026
BNP Paribas971KUS$23.7M−98,114Nov 12, 2026
Schwab958KUS$23.4M+71,934Nov 16, 2026
Northern Trust912KUS$22.3M−21,182Nov 16, 2026
Baillie Gifford & Co823KUS$20.1M+509KNov 9, 2026
Duquesne Family Office LLC700KUS$17.1M+546KNov 16, 2026
Qube Research & Technologies Ltd634KUS$15.5M+440KNov 13, 2026
Rtw Investments, LP570KUS$13.9MNo changeNov 16, 2026
Bank of America525KUS$12.8M−196KNov 16, 2026
Contrarius Group Holdings Ltd522KUS$12.8M−1.09MNov 10, 2026
JPMorgan511KUS$12.6M−4,188Nov 12, 2026
IQ EQ FUND MANAGEMENT (IRELAND) Ltd507KUS$12.4M+51,186Nov 13, 2026
Marshall Wace, LLP483KUS$11.8M+4,519Nov 13, 2026
Elmind Capital, LP476KUS$11.6MNo changeNov 16, 2026
Affinity Asset Advisors, LLC450KUS$11MNewNov 13, 2026
ADAR1 Capital Management, LLC421KUS$10.3MNewNov 16, 2026
Susquehanna414KUS$10.1M+112KNov 16, 2026
BNY357KUS$8.72M−6,018Nov 5, 2026
First Trust349KUS$8.53M+170KNov 12, 2026
Foresite Capital Management VI LLC330KUS$8.07MNo changeNov 16, 2026
Alphabet Inc.322KUS$7.86MNo changeNov 5, 2026
Kingdon Capital Management, L.L.C.310KUS$7.57MNewNov 16, 2026
Peregrine Investment Management Inc309KUS$7.56M+239KNov 10, 2026
Jump Financial, LLC300KUS$7.33MNewNov 13, 2026
Nuveen252KUS$6.15M+6,270Nov 10, 2026
Pictet Asset Management Holding SA247KUS$6.06M−3,686Nov 3, 2026
Edgestream Partners, L.P.245KUS$6M+149KNov 9, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.222KUS$5.43M+64,916Nov 16, 2026
American Century218KUS$5.33M+13,493Nov 20, 2026
Mackenzie211KUS$5.15M+25,022Nov 2, 2026
Federated Hermes, Inc.203KUS$4.97M+78,431Nov 12, 2026

This page holds 50 of 255 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
ARK Innovation ETF6.08MUS$155M−459KJul 31, 2026
Fidelity Growth Company Fund3.46MUS$114M+241KMay 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF3.38MUS$116M+128KJun 30, 2026
Vanguard Total Stock Market Index Fund3.27MUS$112M+176KJun 30, 2026
iShares Russell 2000 ETF2.55MUS$87.3M+206KJun 30, 2026
Vanguard Small-Cap Index Fund2.36MUS$81M+128KJun 30, 2026
ARK Genomic Revolution ETF2.3MUS$58.8M+92,647Jul 31, 2026
Vanguard Small-Cap Growth Index Fund1.36MUS$46.7M+111KJun 30, 2026
Vanguard Extended Market Index Fund1.14MUS$39.2M+41,019Jun 30, 2026
Fidelity Small Cap Index Fund1.08MUS$27.7M+139KJul 31, 2026
Show 50 holders
HolderSharesValueChangeAs of
Fidelity Growth Company K6 Fund980KUS$32.3M+54,934May 31, 2026
T. Rowe Price Health Sciences Fund, Inc.842KUS$28.9M−252KJun 30, 2026
iShares Russell 2000 Growth ETF820KUS$28.2M+43,479Jun 30, 2026
Fidelity Series Growth Company Fund820KUS$27M−61,400May 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund819KUS$28.1M+60,100Jun 30, 2026
iShares Biotechnology ETF664KUS$22.8M−27,665Jun 30, 2026
Fidelity Extended Market Index Fund511KUS$16.8M−7,525May 31, 2026
Select Pharmaceuticals Portfolio501KUS$16.5M+85,200May 31, 2026
Vanguard Russell 2000 Index Fund491KUS$16.2M+17,440May 31, 2026
Schwab U.S. Small-Cap ETF476KUS$15.7M−5,125May 31, 2026
Vanguard Explorer Fund454KUS$11.6M+257KJul 31, 2026
U.S. Small Cap Portfolio445KUS$11.3MNo changeJul 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund427KUS$14.1MNo changeMay 31, 2026
T. Rowe Price New Horizons Fund, Inc.413KUS$14.2MNewJun 30, 2026
Fidelity Capital Appreciation Fund364KUS$9.28MNo changeJul 31, 2026
Dimensional U.S. Small Cap ETF330KUS$8.43M+9,535Jul 31, 2026
U.S. Micro Cap Portfolio326KUS$8.32M+289Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF279KUS$7.12M+39,771Jul 31, 2026
Vanguard Health Care Index Fund274KUS$9.03M+1,695May 31, 2026
Select Biotechnology Portfolio245KUS$8.07MNo changeMay 31, 2026
Schwab Small-Cap Index Fund241KUS$6.15M+31,096Jul 31, 2026
U.S. Core Equity 2 Portfolio216KUS$5.5MNo changeJul 31, 2026
First Trust Small Cap Growth AlphaDEX Fund205KUS$5.22M+107KJul 31, 2026
Fidelity Total Market Index Fund185KUS$6.08MNo changeMay 31, 2026
Master Small Cap Index Series182KUS$6.25M+26,597Jun 30, 2026
BlackRock Health Sciences Opportunities Portfolio168KUS$5.53MNo changeMay 29, 2026
Avantis U.S. Small Cap Equity ETF167KUS$5.49M+29,483May 31, 2026
American Beacon ARK Transformational Innovation Fund155KUS$5.32M−68,857Jun 30, 2026
Fidelity Series Total Market Index Fund152KUS$5.01M+7,139May 31, 2026
iShares Core S&P Total U.S. Stock Market ETF135KUS$4.64M+3,264Jun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF134KUS$3.41M−25,312Jul 31, 2026
Large-Cap Growth Portfolio129KUS$4.43M+7,000Jun 30, 2026
Nuveen Small Cap Blend Index Fund128KUS$3.26M+12,687Jul 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares114KUS$2.92M−71,727Jul 31, 2026
U.S. Core Equity 1 Portfolio112KUS$2.86MNo changeJul 31, 2026
EQ/2000 Managed Volatility Portfolio108KUS$3.7M+7,972Jun 30, 2026
Nuveen Equity Index Fund103KUS$2.64MNo changeJul 31, 2026
First Trust Small Cap Core AlphaDEX Fund102KUS$2.59M+43,559Jul 31, 2026
T. Rowe Price Small-Mid Cap ETF101KUS$3.47M+55,439Jun 30, 2026
iShares Russell 2000 Value ETF94,178US$3.23MNewJun 30, 2026

This page holds 50 of 245 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Evans John M.
Director, Officer: CEO
Sale25,000USD 23.98US$600KOct 16, 2026
Evans John M.
Director, Officer: CEO
Sale25,000USD 23.57US$589KOct 15, 2026
Cavanagh Bethany J
Officer: SVP, Finance and Treasurer
Sale187USD 24.41US$4,565Oct 1, 2026
Simon Amy
Officer: Chief Medical Officer
Sale16,667USD 25.74US$429KJul 27, 2026
Simon Amy
Officer: Chief Medical Officer
Sale373USD 34.73US$12,954Jun 30, 2026
Evans John M.
Director, Officer: CEO
Sale23,100USD 34.26US$791KJun 30, 2026
Evans John M.
Director, Officer: CEO
Sale1,900USD 34.84US$66,196Jun 30, 2026
Evans John M.
Director, Officer: CEO
Sale13,421USD 35.13US$471KJun 29, 2026
Evans John M.
Director, Officer: CEO
Sale11,579USD 35.91US$416KJun 29, 2026
FMR LLC
10% owner, Other: See Remark 1
Sale251,488USD 35.26US$8.87MJun 26, 2026
All 18 trades
InsiderTradeSharesPriceValueDate
FMR LLC
10% owner, Other: See Remark 1
Sale33,372USD 35.12US$1.17MJun 25, 2026
Ciaramella Giuseppe
Officer: President
Sale11,810USD 24.58US$290KApr 1, 2026
Bellon Christine
Officer: Chief Legal Officer
Sale5,956USD 24.58US$146KApr 1, 2026
Cavanagh Bethany J
Officer: SVP, Finance and Treasurer
Sale3,242USD 24.58US$79,688Apr 1, 2026
Simon Amy
Officer: Chief Medical Officer
Sale6,700USD 24.58US$165KApr 1, 2026
Evans John M.
Director, Officer: CEO
Sale30,078USD 24.58US$739KApr 1, 2026
Evans John M.
Director, Officer: CEO
Sale25,000USD 22.76US$569KMar 31, 2026
Evans John M.
Director, Officer: CEO
Sale25,000USD 22.37US$559KMar 30, 2026

Big stakes

HolderStakeSharesDate
FMR LLC12.60%12.8MDec 31, 2025
ARK Investment Management LLC11.43%11.8MSep 30, 2026
Farallon Capital Management, L.L.C.9.99%10.3MJun 30, 2026
BlackRock, Inc.7.50%7.5MMar 31, 2025
State Street Corp5.20%5.23MDec 31, 2025
Vanguard Capital Management LLC5.02%5.12MMar 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Nelsen
Other companies: City Therapeutics, Inc. (Board Director · Since at least Oct 19, 2026); Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Lyell Immunopharma, Inc. (Director · Jun 16, 2021 – Jun 14, 2024 · Past); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 30, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Apr 13, 2021 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 18, 2020 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 2, 2021 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 8, 2017 · Past); Bellerophon Therapeutics Inc (Director · Feb 12, 2015 – Feb 13, 2015 · Past); Juno Therapeutics Inc (Director · Dec 18, 2014 – Mar 5, 2018 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Nov 9, 2015 · Past); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Oct 4, 2013 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Mar 3, 2017 · Past); Kythera Biopharmaceuticals Inc (Director · Oct 10, 2012 – Aug 14, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Jun 7, 2012 · Past); Adolor Corp (Director · May 18, 2006 – May 17, 2007 · Past)
Director · Feb 5, 2020 – Mar 31, 2021 · Past
John M. Maraganore
Other companies: City Therapeutics, Inc. (Executive Chair · Since at least Oct 19, 2026); Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Jan 29, 2026); Rapport Therapeutics, Inc. (Venture Partner, ARCH Venture Partners and Atlas Ventures · Since at least Jun 6, 2024); Kymera Therapeutics, Inc. (Director · Since at least Jan 17, 2022); Alnylam Pharmaceuticals, Inc. (Director · Since at least May 12, 2006); Instil Bio, Inc. (Director · Jun 11, 2025 – Nov 4, 2026 · Past); ProKidney Corp. (Director · Jul 11, 2022 – Jun 29, 2023 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Dec 31, 2022 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Sep 14, 2017 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Oct 10, 2012 · Past)
Board Member · Since at least Nov 5, 2021
Kristina Burow
Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Jan 30, 2025); Boundless Bio, Inc. (Director · Since at least Mar 27, 2024); Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Scholar Rock Holding Corporation (Director · Since at least May 23, 2018); Metacrine Inc (Director · Sep 15, 2020 – May 24, 2021 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 21, 2020 · Past); Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 8, 2023 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Receptos Inc (Director · Aug 25, 2015 – Aug 25, 2015 · Past)
Director · Feb 5, 2020 – Jun 6, 2023 · Past
Graham Cooper
Other companies: Kezar Life Sciences, Inc. (Director · Since at least Jun 20, 2018); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Applied Molecular Transport Inc (Director · Jun 4, 2020 – Jan 27, 2022 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Assembly Biosciences, Inc. (See Remarks · Mar 8, 2018 – Mar 29, 2019 · Past); Eiger Biopharmaceuticals Inc (Director · Jan 29, 2014 – Jun 4, 2015 · Past); Receptos Inc (Chief Financial Officer · May 8, 2013 – Aug 27, 2015 · Past); Geron Corporation (EVP, Bus Dev & CFO · Jan 5, 2012 – May 17, 2012 · Past); Orexigen Therapeutics Inc (CFO and Treasurer · Apr 25, 2007 – Jan 18, 2011 · Past)
Director · Since at least Feb 5, 2020
Carole Ho
Other companies: Eli Lilly and Company (Executive Vice President and President, Lilly Neuroscience · Since at least Dec 31, 2025); Royalty Pharma plc (Director · Since at least Jul 17, 2025); Denali Therapeutics Inc. (Chief Medical Officer · Since at least Apr 1, 2019); NGM Biopharmaceuticals Inc (Director · Jun 5, 2020 – Apr 5, 2024 · Past)
Director · Since at least Feb 5, 2020
Christi Shaw
Other companies: Kyverna Therapeutics, Inc. (Executive Chairperson · Since at least Sep 16, 2024); Avantor, Inc. (Director · May 16, 2019 – May 11, 2023 · Past); Eli Lilly and Company (SVP and Pres., Lilly Bio-Meds · Apr 3, 2017 – May 3, 2019 · Past)
Board Member · Since at least Dec 13, 2023
Kathleen E Walsh
Other companies: LifeMD, Inc. (Director · Dec 15, 2022 – Dec 15, 2022 · Past); WellCare Health Plans Inc (Director · May 23, 2018 – Jan 23, 2020 · Past); Imprivata Inc (Director · Feb 24, 2016 – Sep 16, 2016 · Past)
Director · Since at least Jan 10, 2021
Sravan Emany
Other companies: Kyverna Therapeutics, Inc. (Independent Director · Since at least Feb 24, 2026); Assertio Holdings, Inc. (Director · Since at least Nov 14, 2023); Ironwood Pharmaceuticals, Inc. (SVP, COO and CFO · Dec 6, 2021 – Nov 18, 2024 · Past)
Chief Financial Officer · Since at least Dec 19, 2024
Chirfi Guindo
Other companies: Merck & Company, Inc. (EVP, Access, Policy & Comms · Since at least Jul 1, 2022); Biogen Inc. (Head of Glob Prod Strat & Com · Nov 7, 2017 – Feb 18, 2022 · Past)
Board Member · Since at least Dec 2, 2024
Terry-Ann Burrell
Other companies: Rapport Therapeutics, Inc. (Director · Jun 6, 2024 – Jun 6, 2024 · Past); Recursion Pharmaceuticals, Inc. (Director · Apr 15, 2021 – Jul 1, 2024 · Past)
Chief Financial Officer · Feb 5, 2020 – Apr 26, 2024 · Past
All 22 people
PersonSeat
John Evans
Other companies: Verve Therapeutics Inc (Director · Jun 16, 2021 – Jun 9, 2022 · Past)
Chief Executive Officer and Board Member · Since at least Feb 5, 2020
Amy SimonChief Medical Officer · Since at least Mar 16, 2023
Bethany CavanaghSenior Vice President of Finance, Treasurer and Principal Accounting Officer · Since at least Aug 9, 2024
Christine BellonChief Legal Officer · Since at least Mar 16, 2023
Eric FosterChief Commercial Officer · Since Sep 1, 2026
Giuseppe CiaramellaPresident · Since at least Feb 5, 2020
Gopi ShankerChief Scientific Officer · Since at least Jun 18, 2026
Kate WalshBoard Member · Since at least Nov 4, 2026
Manmohan SinghChief Technology Officer · Since at least Nov 5, 2026
Mark FishmanIndependent Lead Director · Since at least Feb 5, 2020
Stephen C KnightDirector · Feb 5, 2020 – Feb 5, 2020 · Past
Susan O’ConnorChief Human Resources Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Beam Therapeutics Inc.